*仅供医学专业人士阅读参考
2024 ASCO抢先看!
整理 | 是橘不是桔
2024年美国临床肿瘤学会(ASCO)年会即将于美国时间5月31日至6月4日在芝加哥盛大召开。作为世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议之一,ASCO年会每年都汇集了众多世界一流的肿瘤学专家,共同探讨当前最前沿的临床肿瘤学科研成果和肿瘤治疗技术,很多重要的研究发现和成果也会选择在ASCO年会上进行首次发布。
日前,ASCO年会摘要标题已公布,重磅研究亮点不断!小编特此整理部分胃食管癌以及结直肠癌领域全体会议、口头摘要、快速口头摘要以及临床科学研讨会的重磅研究标题,供您参考!
图1 ASCO官网截图
胃食管癌领域精彩研究不断
■摘要号:LBA1
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy(FLOT protocol) to neoadjuvant chemoradiation(CROSS protocol) in patients with adenocarcinoma of the esophagus(ESOPEC trial)
前瞻性随机多中心III期ESOPEC研究:比较食管腺癌患者围手术期化疗(FLOT方案)和新辅助放化疗(CROSS方案)
汇报者:Jens Hoeppner,德国比勒费尔德大学
■摘要号:LBA4001
Effect of chemotherapy/targeted therapy alone vs chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction:The IKF-575/RENAISSANCE phase III trial
III期IKF-575/RENAISSANCE研究:比较单一化疗/靶向治疗与化疗/靶向治疗后根治性手术切除对胃或胃食管交界处(GC/GEJ)局限转移性腺癌患者生存期和生活质量的影响
汇报者:Salah-Eddin Al-Batran,德国法兰克福大学癌症中心
■摘要号:LBA4002
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer:the ARMANI phase III trial
III期ARMANI研究:雷莫西尤单抗+紫杉醇 vs 以奥沙利铂为基础的化疗方案用于HER2阴性晚期GC/GEJ癌患者的维持治疗
汇报者:Filippo Pietrantonio,意大利国家肿瘤研究所基金会
■摘要号:4000
A phase II/III study of peri-operative nivolumab(nivo) and ipilimumab(ipi) in patients(pts) with locoregional esophageal(E) and gastroesophageal junction(GEJ) adenocarcinoma:Results of the neoadjuvant pathologic complete response(pCR) rate(ECOG-ACRIN EA2174)
II/III期ECOG-ACRIN EA2174研究:围手术期纳武利尤单抗和伊匹木单抗治疗局部区域食管(E)和GEJ腺癌患者的新辅助病理完全缓解(pCR)率结果
汇报者:Jennifer Eads,宾夕法尼亚大学艾布拉姆森癌症中心
■摘要号:4009
Efficacy of disitamab vedotin(RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma:A multicenter,single-arm,phase II trial(RCTS)
维迪西妥单抗(RC48)+替雷利珠单抗+S-1一线治疗HER2过表达晚期GC/GEJ腺癌的疗效:一项多中心、单臂、II期研究(RCTS)
汇报者:李松教授,山东大学齐鲁医院
■摘要号:4012
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction(G/GEJ) cancer who failed immunochemotherapy:A multicenter, double-blind, randomized trial
免疫化疗失败的晚期G/GEJ癌患者,卡度尼利单抗+pulocimab和紫杉醇作为二线疗法的疗效和安全性:一项多中心、双盲、随机试验
汇报者:张小田教授,北京大学肿瘤医院
■摘要号:4013
Use of artificial intelligence–based digital pathology to predict outcomes for immune checkpoint inhibitor therapy in advanced gastro-esophageal cancer
利用基于人工智能的数字病理学预测晚期胃食管癌免疫检查点抑制剂(ICI)疗法的疗效
汇报者:Feyisope Eweje,美国斯坦福大学医学院
结直肠癌热点研究即将公布,
值得期待!
■摘要号:LBA3501
Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION):An international, multicenter, phase III randomized controlled trial
国际多中心III期随机对照COLLISION研究:对比手术和热消融治疗小体积结直肠癌(CRC)肝转移的结果
汇报者:Martijn Meijerink,荷兰阿姆斯特丹大学
■摘要号:LBA3502
Primary outcome analysis of the ORCHESTRA trial:A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer
ORCHESTRA试验的主要结局分析:多器官转移性结直肠癌(mCRC)患者在接受一线姑息性系统疗法的基础上加用肿瘤切除术的随机III期试验
汇报者:Elske Gootjes,荷兰阿姆斯特丹大学
■摘要号:LBA3504
NEOPRISM-CRC:Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer
NEOPRISM-CRC研究:根据肿瘤突变负荷进行分层,对高风险II期或III期dMMR/MSI-H CRC进行帕博利珠单抗新辅助治疗
汇报者:Kai-Keen Shiu,英国伦敦大学学院癌症研究所
■摘要号:LBA3510
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)
III期CodeBreaK 300研究的总生存期(OS)数据:Sotorasib联合panitumumab(soto+pani)对比研究者选择方案治疗KRAS G12C突变mCRC患者
汇报者:Marwan Fakih,美国希望之城综合癌症中心
■摘要号:LBA3511
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors(TNTCRT):A multicenter,randomized,open-label,phase 3 trial
多中心、随机、开放标签III期TNTCRT研究:对具有高危因素的局部晚期CRC患者进行全程新辅助长期放疗对比同步放化疗
汇报者:王辛教授,四川大学华西医院
■摘要号:LBA3512
Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer
错配修复缺陷(dMMR)局部晚期CRC对PD-1抑制剂单一治疗的持久完全缓解
汇报者:Andrea Cercek,美国纪念斯隆-凯特琳癌症中心
■摘要号:108
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer:Overall survival and updated 5-year results from the randomized DYNAMIC trial
ctDNA分析指导II期结肠癌的辅助治疗:DYNAMIC研究的OS率和最新5年随访结果
汇报者:Jeanne Tie,澳大利亚彼得·麦卡勒姆癌症中心
■摘要号:3500
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases:A prospective multicentric randomized trial (TRANSMET)
一项前瞻性多中心随机TRANSMET研究:探索化疗和肝移植对比单纯化疗治疗明确不可切除的CRC肝转移患者
汇报者:Rene Adam,巴黎萨克雷大学
■摘要号:3503
Nivolumab(NIVO) plus ipilimumab(IPI) vs chemotherapy(chemo) as first-line(1L) treatment for microsatellite instability-high/mismatch repair-deficient(MSI-H/dMMR) metastatic colorectal cancer(mCRC):Expanded efficacy analysis from CheckMate 8HW
纳武利尤单抗联合伊匹木单抗与化疗作为高度微卫星不稳定性(MSI-H)/dMMR转移性mCRC的一线治疗:来自 CheckMate 8HW研究的扩展疗效分析结果
汇报者:Heinz-Josef Lenz,美国南加州大学诺里斯综合癌症中心
■摘要号:3505
Neoadjuvant treatment of IBI310(anti-CTLA-4 antibody) plus sintilimab(anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer:Results from a randomized,open-labeled,phase Ib study
IBI310(抗CTLA-4抗体)联合信迪利单抗(抗PD-1抗体)作为MSI-H/dMMR CRC患者的新辅助治疗: 一项随机、开放标签的Ib期研究结果
汇报者:徐瑞华教授,中山大学肿瘤防治中心
■摘要号:3506
FU/FA maintenance therapy with or without panitumumab(pmab) in RAS wild-type metastatic colorectal cancer(mCRC)(PanaMa, AIO KRK 0212):Updated efficacy analyses
AIO KRK 0212研究:RAS野生型mCRC的FU/FA维持治疗联合或不联合Panitumumab(pmab)的最新疗效分析
汇报者:Dominik Modest,德国柏林夏里特医学院
■摘要号:3507
Acquired gene alteration patterns and post-progression survival:PARADIGM study analysis
获得性基因改变模式与进展后生存:PARADIGM研究分析
汇报者:Hiroyuki Uetake,日本东京医科齿科大学
■摘要号:3508
ARC-9:A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)
ARC-9研究:一项随机研究评估在既往接受过治疗的mCRC患者中基于etrumadenant的联合治疗方案的疗效
汇报者:Zev Wainberg,美国加州大学洛杉矶分校大卫格芬医学院
■摘要号:3509
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)
Tucatinib和曲妥珠单抗治疗HER2阳性mCRC:II期MOUNTAINEER研究的最终结果
汇报者:John Strickler,美国杜克大学医学中心
■摘要号:3513
Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer。
人乳头瘤病毒(HPV)ctDNA检测作为肛门癌预后生物标志物的时间依赖性
汇报者:Van Morris,美国MD安德森癌症中心
■摘要号:3515
First-in-human study of ABBV-400,a novel c-Met–targeting antibody-drug conjugate,in advanced solid tumors:Results in colorectal cancer
ABBV-400(新型c-Met靶向抗体-药物偶联物)用于晚期实体瘤的首次人体试验:CRC研究结果
汇报者:Manish Sharma,START Midwest
■摘要号:3516
Three-year disease-free survival after transanal vs。laparoscopic total mesorectal excision for rectal cancer(TaLaR):A randomized clinical trial
TaLaR研究:探索经直肠或腹腔镜进行全直肠系膜切除术治疗直肠癌后的三年无病生存率
汇报者:康亮教授,中山大学附属第六医院
■摘要号:3517
Updated results from ERAS-007 plus encorafenib and cetuximab(EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer(CRC) in the phase 1b/2 HERKULES-3 study
Ⅰ、Ⅱ期HERKULES-3研究:ERAS-007联合Encorafenib和西妥昔单抗 (EC) 在 EC 初治BRAF V600E 突变mCRC患者中的更新结果
汇报者:Aparna Parikh,美国麻省总医院
精彩资讯等你来
责任编辑:Sheep
*医学界力求其发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。